1.
A global survey of potential acceptance of a COVID-19 vaccine
by Lazarus, Jeffrey V
Nature medicine, 2021-02, Vol.27 (2), p.225-228
2.
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
by Monin, Leticia
The lancet oncology, 2021-06, Vol.22 (6), p.765-778
3.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
by Feng, Shuo
Nature medicine, 2021-11, Vol.27 (11), p.2032-2040
4.
Looking beyond COVID-19 vaccine phase 3 trials
by Kim, Jerome H
Nature medicine, 2021-02, Vol.27 (2), p.205-211
5.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
by Ewer, Katie J
Nature medicine, 2021-02, Vol.27 (2), p.270-278
6.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
by Wibmer, Constantinos Kurt
Nature medicine, 2021-04, Vol.27 (4), p.622-625
7.
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
by Guebre-Xabier, Mimi
Vaccine, 2020-11-25, Vol.38 (50), p.7892-7896
8.
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
by Choi, Angela
Nature medicine, 2021-11, Vol.27 (11), p.2025-2031
9.
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
by Chen, Rita E
Nature medicine, 2021-04, Vol.27 (4), p.717-726
10.
The demand for a COVID-19 vaccine in Ecuador
by Sarasty, Oscar
Vaccine, 2020-12-03, Vol.38 (51), p.8090-8098
11.
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
by Ura, Takehiro
Vaccine, 2021-01-08, Vol.39 (2), p.197-201
12.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
by Barrett, Jordan R
Nature medicine, 2021-02, Vol.27 (2), p.279-288
13.
Vaccine development for emerging infectious diseases
by Excler, Jean-Louis
Nature medicine, 2021-04, Vol.27 (4), p.591-600
14.
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
by Xie, Xuping
Nature medicine, 2021-04, Vol.27 (4), p.620-621
15.
COVID-19 vaccination: the VOICE for patients with cancer
by van der Veldt, Astrid A.M
Nature medicine, 2021-04, Vol.27 (4), p.568-569
16.
A government-led effort to identify correlates of protection for COVID-19 vaccines
by Koup, Richard A
Nature medicine, 2021-09, Vol.27 (9), p.1493-1494
17.
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
by Shroff, Rachna T
Nature medicine, 2021-11, Vol.27 (11), p.2002-2011
18.
Importance of COVID-19 vaccine efficacy in older age groups
by Sadarangani, Manish
Vaccine, 2021-04-08, Vol.39 (15), p.2020-2023
19.
Eight unanswered questions about the COVID-19 pandemic
by May, Mike
Nature medicine, 2021-12, Vol.27 (12), p.2058-2061
20.
COVID-19 vaccination in immunocompromised patients
by Sonani, Bhavin
Clinical rheumatology, 2021-01-11, Vol.40 (2), p.797-798
